8-K: 23andMe Reports 33% Revenue Drop in Q3, Adjusts Full Year Guidance

23andMe's Q3 fiscal year 2024 results show a significant revenue decrease of 33% year-over-year, alongside a large net loss, prompting an adjustment to the company's full-year financial guidance.

Summary

• 23andMe reported a total revenue of $44.7 million for the third quarter of fiscal year 2024, a 33% decrease compared to $66.9 million in the same quarter of the previous year.
• The revenue decline was primarily due to lower research revenue following the end of the GSK collaboration exclusivity in July 2023 and reduced sales of PGS kits.
• Operating expenses increased significantly to $301 million, up from $128 million year-over-year, largely due to a $199 million non-cash goodwill impairment charge.
• The company's net loss for the quarter was $278 million, compared to a net loss of $92 million in the same period last year.
• Adjusted EBITDA for the quarter was a loss of $48 million, compared to a loss of $43 million in the prior year.
• 23andMe ended the quarter with $242 million in cash and cash equivalents, down from $387 million at the end of March 2023.
• The company has adjusted its full-year revenue guidance to a range of $215 million to $220 million, with a net loss between $525 million and $520 million, and an adjusted EBITDA deficit between $185 million and $180 million.

Sentiment

Score: 3

Explanation: The document indicates significant financial challenges, including a large revenue drop, increased losses, and a substantial goodwill impairment. While there are some positive developments in new products and therapeutics, the overall financial picture is concerning, leading to a low sentiment score.

Positives

• 23andMe secured a $20 million upfront payment from GSK for a non-exclusive data license, highlighting the value of their genetic database.
• The launch of 23andMe+ Total Health introduces a new advanced health membership service.
• The expansion of the BRCA1/BRCA2 report provides more comprehensive genetic risk information.
• FDA acceptance of the IND filing for 23ME-01473 marks a significant step in their therapeutics pipeline.
• The company is prioritizing margin expansion and progressing toward cash flow profitability within its consumer businesses.

Negatives

• Total revenue decreased by 33% year-over-year, primarily due to the end of the GSK exclusivity and lower PGS kit sales.
• Operating expenses significantly increased due to a $199 million non-cash goodwill impairment charge.
• The net loss for the quarter was $278 million, a substantial increase from the previous year.
• Adjusted EBITDA showed a larger loss compared to the same period last year.
• Cash and cash equivalents decreased from $387 million to $242 million since March 31, 2023.
• The company has adjusted its full-year guidance downwards.

Risks

• The end of the GSK collaboration exclusivity has significantly impacted research revenue.
• Lower sales of PGS kits and telehealth orders have negatively affected consumer services revenue.
• The large goodwill impairment charge indicates a potential overvaluation of assets.
• The company is experiencing a significant cash burn, as evidenced by the decrease in cash reserves.
• The adjusted full-year guidance suggests continued financial challenges.

Future Outlook

The company has adjusted its full-year revenue guidance to a range of $215 million to $220 million, with a net loss between $525 million and $520 million, and an adjusted EBITDA deficit between $185 million and $180 million. They are prioritizing margin expansion and progressing toward cash flow profitability.

Management Comments

• Anne Wojcicki, Co-Founder & CEO of 23andMe, stated that the company had a very productive third quarter with meaningful strategic progress across all three business lines.
• She highlighted the encouraging Phase 1 data for 23ME-00610, the advancement of the 23ME-01473 program, the introduction of 23andMe Total Health, and the first non-exclusive data deal with GSK.

Industry Context

The decrease in revenue due to the end of the GSK exclusivity highlights the challenges of relying on large collaborations for revenue. The company's focus on new membership services and therapeutics development reflects a broader trend in the personalized medicine and biotech industries to diversify revenue streams and develop proprietary assets.

Comparison to Industry Standards

• The 33% revenue decrease is significant and worse than many comparable biotech companies, which often experience more stable revenue streams from product sales or ongoing collaborations.
• The large goodwill impairment charge is unusual and suggests that the company may have overvalued previous acquisitions or partnerships, which is not a common occurrence in the industry.
• The adjusted EBITDA loss of $48 million is also concerning, as many biotech companies at this stage are either closer to profitability or have a clear path to profitability through product sales or licensing agreements.
• Companies like Myriad Genetics (MYGN) and Invitae (NVTA), which also offer genetic testing services, have faced similar challenges in achieving profitability, but 23andMe's revenue decline is more pronounced.
• The development of 23ME-01473 is a positive step, but it is still in early stages compared to other immuno-oncology assets in development by companies like Bristol Myers Squibb (BMY) or Merck (MRK).

Stakeholder Impact

• Shareholders will likely be negatively impacted by the significant revenue decrease, increased losses, and reduced guidance.
• Employees may be affected by ongoing cost-cutting measures and workforce reductions.
• Customers may benefit from new services like 23andMe+ Total Health, but may also be concerned about the company's financial stability.
• Suppliers and creditors may face increased risk due to the company's financial challenges.

Next Steps

• The company expects to initiate a Phase 1 dose escalation study for 23ME-01473 in the first half of 2024.
• The company will continue to enroll patients in the Phase 2a portion of the 23ME-00610 clinical trial, with initial efficacy and cohort data expected in 2024.
• 23andMe will focus on margin expansion and progressing toward cash flow profitability within its consumer businesses.
• The company will continue to develop new services like the Total Health membership.

Key Dates

Keywords

23andMe, genetics, biopharmaceutical, revenue, EBITDA, financial results, data license, GSK, FDA, IND, therapeutics, consumer services, BRCA1, BRCA2, health membership, goodwill impairment